Objectives/Hypothesis: Chronic Rhinosinusitis (CRS) is accompanied by evidence of a vigorous adaptive immune response, and emerging studies demonstrate that some nasal polyps manifest a polyclonal autoantibody response. We previously found that antibodies against BP180, a component of the hemidesmosome complex and the dominant epitope in autoimmune bullous pemphigoid, were found at elevated levels in nasal polyp tissue. Given the critical role of hemidesmosomes in maintaining epithelial integrity, we sought to investigate the distribution of BP180 in nasal tissue and evaluate for evidence of systemic autoimmunity against this antigen in CRS.
INTRODUCTION
Chronic rhinosinusitis (CRS) is a prevalent chronic inflammatory condition of the paranasal sinuses affecting approximately 8% of the U.S. population. Clinical experience and analysis of the inflammatory infiltrate associated with CRS suggests that it manifests phenotypically in two different forms-one with nasal polyps (CRSwNP) and another without (CRSsNP). 1, 2 Previous studies by our group have highlighted that B-cells play an important role in CRSwNP, with locally increased levels of B-cell activating factor (BAFF); IL6, a cytokine involved in B-cell maturation and plasma cell differentiation; chemokines associated with B-cell recruitment; and elevated levels of class-switched immunoglobulins such as IgA and IgG, when compared with CRSsNP and normal controls. 3, 4 The systemic overexpression of some of these pro-inflammatory factors in mouse models results in autoimmunity, and it has been hypothesized that a similar effect could occur, at least locally, in CRSwNP.
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Send correspondence to Bruce Tan, MD, Department of Otolaryngology-Head and Neck Surgery, Feinberg School of Medicine, Northwestern University, 676 N St Clair, Suite 1325, Chicago, IL 60611. E-mail: btan@nmff.org the nasal polyp tissue, but it was found that significantly higher levels of anti-dsDNA were correlated with recurrent nasal polyps requiring revision surgery. These data suggest that a previously undescribed autoimmune response is present in CRSwNP, and suggest a novel role for autoimmunity in CRSwNP. The antigenic targets of these autoantibodies have only begun to be characterized, and it remains unclear if this represents a local or a systemic autoimmune response.
The microarray analysis also suggested that increased levels of anti-BP180 IgG autoantibodies are present in nasal polyp tissue (Fig. 1) . BP180 (BPA2/collagen XVII) is a transmembrane glycoprotein that is associated with the hemidesmosome complex on the basal surface of epidermal keratinocytes, and it functions to maintain adhesion of the stratified epithelia to the basement membrane. 6, 7 This protein is known to be a primary target of IgG autoantibodies in several autoimmune blistering diseases, including bullous pemphigoid. [8] [9] [10] The expression of BP180 and its localization to the epithelial-ECM junction is best characterized in skin, but has also been shown in cultured human bronchial epithelial cells. 11 Since bullous pemphigoid is not known to have nasal or airway manifestations, the presence, distribution and function of BP180 in the nose has direct relevance to the potential pathogenicity of anti-BP180 autoantibodies in nasal polyps.
Previous studies in our lab have demonstrated a reduction in several molecules of the epidermal differentiation complex, including psoriasin, calprotectin, and SPINK5 in CRS, suggesting an underlying epithelial barrier defect that may contribute to disease pathogenesis. 1, 12, 13 An anti-epithelial antibody response affecting basement membrane integrity in CRSwNP would have important implications for the barrier dysfunction observed in this disease. This study investigated the expression and distribution of BP180 in sinonasal tissue and nasal epithelial cells, and the presence of systemic anti-BP180 autoantibodies in patients with CRS.
MATERIALS AND METHODS
All protocols were reviewed and approved by a Northwestern University Feinberg School of Medicine Institutional Review Board. Informed consent was obtained from all subjects from whom clinical information was collected. De-identified specimens obtained from subjects during routine surgical care were deemed exempt from informed consent.
Cell Culture
Primary nasal epithelial cells (NECs) were collected and cultured as previously described. 3 NECs were maintained in a serum-free bronchial epithelial growth medium (Cambrex, Walkersville, MD). NECs were plated in 10-cm culture plates coated with collagen (Vitrogen; Collagen Biomaterials, Palo Alto, CA). An immortalized line of human epidermal keratinocytes (HEKs) derived from neonatal foreskin (a gift from Dr. Lou Laimins, Northwestern University, Chicago, IL) and known to express BP180 was used as a positive control.
14 HEKs were maintained in defined keratinocyte serum-free medium (DKSFM) (0.07 mM CaCl 2 ) supplemented with a proprietary growth factor mixture (serum-and bovine pituitary extract-free) (Invitrogen, Carlsbad, CA). When cells reached 90% confluence, they were lysed for protein and RNA extraction, or transferred to glass coverslips for cellular immunofluorescence.
Nasal Protein Extraction and Western Blot
BP180 protein expression was assessed in whole-cell extracts of cultured cells, as described previously. 11 Briefly, cells were lysed in a sample buffer consisting of 8 M urea; 1% sodium dodecyl sulfate (SDS) in 10 mM Tris-HCl, pH 6.8; and 15% b-mercaptoethanol. Proteins in the preparation were resolved on a 3% to 8% NuPAGE Tris-Acetate gel (Invitrogen, Carlsbad, CA), and transferred to a polyvinylidene difluoride membrane for immunoblotting (Bio-Rad Laboratories, Hercules, CA). The membranes were incubated with AB79878, a mouse monoclonal IgG antibody against BP180 (Abcam, Cambridge, MA) at a concentration of 1:1000 overnight at 4 C. After washing, they were treated with a goat anti-mouse IgG secondary antibody (Li-Cor Biosciences, Lincoln, NE). Immunoblots were digitalized and quantified with Odyssey imaging software (LiCor Biosciences, Lincoln, NE). Densitometry values for BP180 were normalized to those of the housekeeping gene b-actin.
Real-Time PCR
HEKs and NECs were lysed in RNA lysis buffer supplemented with b-mercaptoethanol, and RNA was extracted according to the manufacturer's protocol (Clontech, Mountain View, CA). Real-time polymerase chain reaction (PCR) was performed using the TaqMan method, as described previously. 15 TaqMan primer and probe sets for BP180 were purchased from ABI (4331182, COL17A1, Hs00166711_m1). The mRNA expression levels of BP180 were normalized to the median expression of the housekeeping gene b-actin and expressed as copies/ng RNA.
Immunofluorescence and Immunohistochemistry
Cells on coverslips were processed for immunofluorescence, as previously described, and treated with 1804b, a mouse monoclonal IgM antibody against BP180 (provided by the Jonathan Jones Lab, Northwestern University, Chicago, IL) at a 12 After washing, cells were incubated with a FITC-conjugated goat anti-mouse IgM secondary antibody (Jackson Immunoresearch Laboratories, West Grove, PA). All preparations were viewed with a confocal laser scanning microscope (LSM 510, Zeiss, Thornwood, NY).
Normal nasal tissue was harvested from individuals without a history of CRS who were undergoing sinonasal surgery for unrelated reasons (e.g., endoscopic skull-base tumor excisions, intranasal procedures for obstructive sleep apnea). Normal human facial skin, redundant after cosmetic surgery procedures, was obtained as a positive control. Tissue specimens were prepared and processed for immunofluorescence and immunohistochemistry, as previously described. 3, 16 For immunofluorescence, tissue sections were incubated with J17, a rabbit polyclonal IgG antibody against BP180 (a gift from Dr. Jonathan Jones, Northwestern University, Chicago, IL) at a concentration of 1:3000. The slides were gently washed in PBS and incubated with goat anti-rabbit IgG Alexa-Fluor conjugated secondary antibody. For immunohistochemistry, tissue sections were incubated with J17 at a concentration of 1:5000 for 1 hour at room temperature. Sections were rinsed and then incubated in biotinylated goat anti-rabbit IgG secondary antibody (Vector Laboratories, Burlingame, CA) for 1 hour at room temperature. All preparations were viewed using an Olympus IX71 Inverted Microscope (Olympus America, Inc., Center Valley, PA).
Patients and Sera
Patients with CRS were recruited from a tertiary care allergy and otolaryngology practice at the Northwestern University Feinberg School of Medicine. The diagnosis of CRSwNP or CRSsNP in this study was based on clinical criteria, as defined by the American Academy of Otolaryngology-Head and Neck Surgery Chronic Rhinosinusitis Task Force. 17 Sera were collected from CRS patients and normal controls without CRS at the time of endoscopic sinus surgery; collection was limited to serum alone; and whole blood was not available for any further hematological assessment.
The population was limited to otherwise healthy adults between the ages of 18 and 80 years. Subjects taking anticoagulants who had received an organ transplant or who had taken oral corticosteroids or antibiotics within the previous 2 weeks were excluded from the study. None of the patients enrolled in this study had a history of autoimmune disease, as determined by a thorough review of each patient's electronic medical record. Details of subjects' characteristics are included in Table I .
Patients' sera were screened for IgG antibodies against BP180 using a standard validated enzyme-linked immunosorbent assay (ELISA) (MBL Diagnostics, Nagoya, Japan), according to the manufacturer's instructions for diagnosis of bullous pemphigoid. 18, 19 Briefly, patient serum was diluted 1:101 with diluent, then incubated on plates coated with recombinant purified BP180NC16a antigen. After washing, plates were incubated with horseradish peroxidase conjugated goat anti-human IgG, followed by development with the substrate solution. Absorbance was read at 450 nm, and results calculated as instructed using the provided standard curve and negative controls. Any positive results were verified by performing indirect immunofluorescence on monkey esophagus (Immco Diagnostics, Buffalo, NY). Tissue sections were incubated with serum at a concentration of 1:40 for 45 minutes, followed with a goat antihuman IgG FITC conjugated secondary antibody (Immco Diagnostics, Buffalo NY). Sections were rinsed in PBS, mounted with 50% glycerol in PBS, and viewed as above.
The relationship between serum levels of anti-BP180 and age and total IgGwere assessed using linear regression, and the R 2 correlation coefficient was determined. Multigroup comparisons were performed using the Kruskal-Wallis test since the distribution of autoantibodies in sera was non-Gaussian and a post hoc Dunn's test was used to evaluate the binary comparisons driving the positive Kruskal-Wallis test. Binary comparisons were carried out using a Mann-Whitney U test. All analyses were performed using software obtained from GraphPad Prism (La Jolla, CA). A 2-tailed P value of less than 0.05 was considered statistically significant.
RESULTS

BP180 Expression in Nasal Epithelial Cells
We first performed Western blot analyses to confirm that BP180 is expressed in nasal epithelial cells. We compared BP180 levels in HEKs (expressed as normalized intensity to b-actin) to those in NECs from two normal donors without a history of CRS (Fig. 2) . NECs from both donors had higher levels of BP180 mRNA compared with keratinocytes, although this was not statistically significant. We next confirmed these results using realtime PCR, in which we compared BP180 mRNA levels in HEKs (expressed in copies BP180/ng RNA) to those in NECs from the same normal donors (Fig. 2) . We again found markedly higher levels of BP180 mRNA in NECs compared to HEKs, demonstrating that the BP180 antigen is in fact expressed in NECs.
We then evaluated the distribution of BP180 within NECs using immunofluorescence and confocal microscopy. We found that BP180 is localized to the basilar surface in cultured NECs grown in submersion, in the region where cells contact the underlying extracellular matrix (Fig. 3) . Similar to its distribution in cultured HEKs, BP180 is distributed in punctate complexes consistent with localization to hemidesmosomes.
Distribution of BP180 in Nasal Epithelium
We compared the distribution of BP180 in normal nasal epithelium to that in normal human skin using immunohistochemistry and immunofluorescence. In human skin, we found the expected distribution of BP180, with staining localized to the basal keratinocytes and basement membrane (Fig. 4) . In nasal epithelium, however, we found diffuse staining present throughout all layers of the epithelium. These results suggest that BP180 is distributed very differently in pseudostratified nasal epithelium versus skin, and may thus serve a different role aside from cellular adhesion to the basement membrane. 
Anti-BP180 Autoantibodies in the Serum of Patients With CRS
We used a commercially available enzyme-linked immunosorbent assay (ELISA) (MBL Diagnostics, Nagoya, Japan), routinely used to diagnose bullous pemphigoid, to screen the serum of patients with CRS for the presence of systemic anti-BP180 autoantibodies. Interestingly, we found an elevated level of anti-BP180 autoantibodies in the serum of patients with CRS (Fig. 5 ). There was a significantly higher level of circulating anti-BP180 autoantibodies in CRSsNP compared with CRSwNP and normal controls (P<0.05). Even more surprising, we found that several patients actually tested positive for bullous pemphigoid according to the kit's specifications, despite having no clinical manifestations of disease. However, when we assessed ELISA-positive samples for specific antibodies using indirect immunofluorescence on monkey esophagus, the serum showed no characteristic binding along the basal surface (data not shown).
In analyzing the clinical and laboratory correlates of serum anti-BP180 autoantibody levels, we found no correlation with total IgG (R 2 50.0227), age (R 2 50.0001), gender (P50.381), or asthma status (P50.666). There was, however, a significant correlation between serum anti-BP180 autoantibody levels and atopy, defined as at least one positive skin test response, with atopic patients having significantly higher levels of serum anti-BP180 than non-atopic patients (P<0.05) (Fig. 6) . Overall, 13.3% of atopic patients with CRS tested positive for bullous pemphigoid using the commercially available ELISA assay.
DISCUSSION
The goal of this study was to characterize the expression and distribution of BP180 in NECs and nasal tissue, and to assess for evidence of systemic autoimmunity against this antigen in CRS. We first performed Western blot analyses and real-time PCR on whole cell extracts of cultured NECs, and confirmed that BP180 is highly expressed at both the protein and mRNA level . Serum levels of anti-BP180 autoantibodies in patients with CRS and normal controls, measured in U/mL. There was a significantly elevated level of serum anti-BP180 in CRSsNP compared to CRSwNP and normal controls. The dotted line represents the cut-off value of 9U/mL, above which the ELISA is considered positive for bullous pemphigoid. CRSsNP5chronic rhinosinusitis without nasal polyps; CRSwNP5chronic rhinosinusitis with nasal polyps. within the cells. We then used immunofluorescence and confocal microscopy to demonstrate that BP180 localizes to the basal surface of cultured, submerged NECs in a punctate distribution, as it does in keratinocytes and bronchial epithelial cells. 11 This implies that BP180 likely plays a similar role in the formation of hemidesmosomes and the anchoring of NECs to the basement membrane. However, we next performed immunofluorescence and immunohistochemistry on nasal tissue, and found that BP180 is diffusely distributed throughout all layers of the epithelium. This is in contrast to the linear distribution of BP180 along the basement membrane that is seen in human skin, and suggests that BP180 may serve a different role and function in the nose, in addition to that of epithelial anchoring. Finally, we previously showed an increased level of anti-BP180 autoantibodies in nasal polyp tissue. 5 Interestingly, we also found that a significant percentage of CRS patients have increased levels of systemic anti-BP180 autoantibodies. These antibodies were judged to be nonpathogenic by the indirect immunofluorescence assay used to confirm a diagnosis of bullous pemphigoid; therefore, they may recognize a distinct epitope or represent a distinct isotype from the anti-BP180 autoantibodies classically associated with bullous pemphigoid.
BP180 is known to be a critical structural adhesion protein in skin. 7 In bullous pemphigoid, autoantibodies against BP180 lead to the separation of the stratified epithelium from the underlying basement membrane, resulting in the characteristic subepidermal blisters seen in the disease. [8] [9] [10] However, previous studies have also established that the hemidesmosome has many roles beyond that of an anchoring complex. Components of the hemidesmosome have been shown to transduce extracellular signals, and thereby regulate cell motility, differentiation, proliferation, and even apoptosis. 20 Recent studies have further identified BP180 as a critical component necessary for the activation of these signaling pathways. 21 Aberrant expression of BP180 has been demonstrated in dysplastic and cancerous epithelial lesions, where distribution of BP180 is seen diffusely throughout all layers of the epithelium. 22, 23 Therefore, it is possible that the diffuse distribution of BP180 in nasal epithelium reflects the altered properties of cell migration and differentiation compared with other epithelial tissues. A unique distribution and function of BP180 in nasal tissue may also explain why there are no known nasal manifestations of bullous pemphigoid.
It has been previously demonstrated that pathogenic anti-BP180 autoantibodies in bullous pemphigoid bind the NC16a noncollagenous domain of the BP180 protein, and it is this epitope that is the target antigen in the commercially available ELISA used for diagnosis. 24 Sakuma-Oyama et al. tested the sensitivity and specificity of the ELISA used in this study, and found that using a cutoff value of 9U/mL was associated with a sensitivity of 89% and a specificity of 98%. 18 Only 3% of normal subjects in this study falsely tested positive for bullous pemphigoid, which is in keeping with the 1.2% false positive rate reported by the manufacturer. These results are echoed by those of Wieland et al. who assessed the prevalence of systemic anti-BP180 antibodies in the normal population. 25 Again, only 3% of the study population falsely tested positive for bullous pemphigoid. Our study found that 13.3% of atopic patients with CRS tested positive for bullous pemphigoid, despite having no systemic manifestations of the disease. All patients that tested positive by ELISA were found to be negative by indirect immunofluorescence, demonstrating that these circulating antibodies are not pathologic in the traditional sense. To our knowledge, ours is the first study to demonstrate significantly elevated levels of circulating anti-BP180 autoantibodies that bind the NC16a noncollagenous domain in a population without history of autoimmune blistering disease.
Previous studies in our lab have demonstrated that increased levels of B-cell attractant chemokines are present in nasal polyp tissue. 26 B-cell accumulation in CRSwNP is associated with increased tissue concentrations of IgG, IgA, and IgE antibodies compared with normal controls, but these increases are not reflected in the systemic circulation. 27, 28 It has also been determined that the local B-cell class switch recombination to IgD occurs constitutively in nasal mucosa, and evidence for class switching to IgE can be found in the nasal mucosa of patients with allergic rhinitis, as well as in the bronchial mucosa of patients with asthma and in the esophageal mucosa of patients with eosinophilic esophagitis. [29] [30] [31] [32] Furthermore, local IgE antibodies against Altenaria can be found at elevated levels in the homogenates of nasal polyps without associated elevations in serum. 28 Similarly, our recent report demonstrated the local production of IgG and IgA anti-dsDNA antibodies in nasal polyps, in addition to increased levels of anti-BP180 autoantibodies. 5 This local autoreactivity is unlikely to correlate with a systemic autoimmune response, given that our previous observations of local autoantibodies were confined to the CRSwNP population, and also given the lack of systemic manifestations of autoimmunity in patients with CRS.
The systemic elevation of anti-BP180 autoantibodies seen in CRS appears associated with atopy but is of Fig. 6 . Serum levels of anti-BP180 autoantibodies by atopic status. There was a significant elevation of serum anti-BP180 in patients with atopy compared to nonatopic patients.
unclear clinical significance as these antibodies are not classically pathologic, resulting in clinical bullous pemphigoid or a specific staining pattern on indirect immunofluorescence. It is possible that atopy may trigger the development of autoreactivity due to epithelial damage and liberation of epitopes. Alternatively, it has been shown that nasal mucosa and tonsils contain resident IgD1IgM-B-cells, which produce immunoglobulins that are intrinsically poly-and autoreactive even in normal, healthy individuals. 32, 33 Thus, these B-cells have been proposed as a "sink" for autoreactive B-cells, and a nasal inflammatory process may result in spillover autoreactive immunoglobulins into the systemic circulation. Studies by Faller et al. have described a similar phenomenon in H. pylori gastritis, in which a subset of patients was found to have increased levels of serum antigastric autoantibodies that correlated with the degree of gastric mucosal atrophy. 34 Further investigation is thus necessary to define the pathologic implications of anti-epithelial autoantibodies in CRS.
Due to the low prevalence of systemic anti-BP180 autoantibodies in CRS, and the failure of these antibodies to bind the basement membrane in studies of indirect immunofluorescence, it is unlikely that antibodies against this epitope will be of value for diagnosis. It is, however, important to note that a subset of patients with CRS may have elevated levels of circulating autoantibodies, and they may falsely test positive for autoimmune disorders such as bullous pemphigoid. The presence of autoreactive antibodies to BP180 in CRS patients raises questions as to whether yet undescribed autoantibodies directed against more specific nasal antigens may be present or detected at higher levels in patients with CRS, and might possibly play a role in the pathogenesis of disease. Experimental models for autoimmune diseases, such as systemic lupus erythematosus, propose that cellular damage or failure to clear self-antigens leads to the breakdown of tolerance and generation of autoimmunity. 35 The presence of systemic, class-switched, self-reactive antibodies against BP180, a critical anchoring protein expressed in nasal mucosa, suggests that similar processes may occur in CRS. However, further studies are needed to answer these questions and to determine whether the systemic autoantibodies detected in CRS play have implications for the efficacy of existing therapies or the customization of new therapies for treating specific CRS patients.
CONCLUSION
BP180, a critical anchoring protein in keratinocytes, is highly expressed in nasal epithelium, and it likely serves a similar function in cellular anchoring to the basement membrane. However, its distribution in nasal tissue is more diffuse throughout the pseudostratified epithelial layer. Thus, BP180 is a relevant epithelial antigen for the local autoantibody response seen in CRSwNP. Surprisingly, nonpathologic anti-BP180 antibodies were elevated in CRS patients, although this association may be linked to atopy. The role of anti-epithelial antibodies in CRS needs further investigation.
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